MedTrace Logo

Outcomes of Tolerating Subretinal Fluid in Type 1 MNV and PCV

NCT05662943 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 135

Last updated 2023-12-14

No results posted yet for this study

Summary

The purpose of the present study was to evaluate the outcomes of type 1 macular neovascularization (MNV), including polypoidal choroidal vasculopathy in patients treated tolerating subretinal fluid (SRF) using Aflibercept in a clinical setting. Approximately 150 patients are anticipated to be enrolled in this study. SRF is a primary type of fluid compartment prevalent in type 1 aneurysmal MNV. In a recent study, the prevalence of SRF during 24-month follow-up period was 36.7% to 38.8% in type 1 MNV and polypoidal choroidal vasculopathy (PCV), 20.0% in type 2 MNV, and 7.7% in type 3 MNV. In addition, patients with SRF showed better visual prognosis in type 1 MNV/PCV. For this reason, type 1 MNV is an appropriate candidate for evaluating the influence of tolerating SRF.

Conditions

  • Polypoidal Choroidal Vasculopathy
  • Choroidal Neovascularization
  • Age-Related Macular Degeneration

Interventions

DRUG

Intravitreal aflibercept injection

Intravitreal injection of aflibercept (0.2 mg / 0,05 ml; Bayer Co. Ltd.,)

Sponsors & Collaborators

  • Kim's Eye Hospital

    lead OTHER

Principal Investigators

  • Jae Hui Kim, M.D. · Kim's Eye Hospital

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-05
Primary Completion
2023-05-31
Completion
2023-11-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05662943 on ClinicalTrials.gov